No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia
Abstract The objective of this study was to correlate resistance mutations of extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases and virulence factors (VF) with 30-day mortality in patients treated with either piperacillin-tazobactam or carbapenems. A post-hoc analysis on 123 patients...
Guardado en:
Autores principales: | , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ae5796eed3b7401d9a83da28e86e78fd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:ae5796eed3b7401d9a83da28e86e78fd |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:ae5796eed3b7401d9a83da28e86e78fd2021-12-02T11:41:24ZNo association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia10.1038/s41598-018-31081-62045-2322https://doaj.org/article/ae5796eed3b7401d9a83da28e86e78fd2018-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-31081-6https://doaj.org/toc/2045-2322Abstract The objective of this study was to correlate resistance mutations of extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases and virulence factors (VF) with 30-day mortality in patients treated with either piperacillin-tazobactam or carbapenems. A post-hoc analysis on 123 patients with ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia treated empirically with piperacillin-tazobactam and carbapenems was performed. Beta-lactamase resistance mutations and VF were identified by whole genome sequencing (WGS). The primary endpoint was 30-day mortality. Multivariate analyses were performed using logistic regression. WGS showed diverse multilocus sequence types (MLST) in 43 K. pneumoniae strains, while ST131 predominated in E. coli strains (57/80). CTX-M was most commonly detected (76/80 [95%] of E. coli; 39/43 [91%] of K pneumoniae.), followed by OXA (53/80 [66%] of E. coli; 34/43 [79%] of K. pneumoniae). A significant correlation was found between the number of genes encoding third-generation cephalosporin-resistant beta-lactamases and 30-day mortality (p = 0.045). The positive association was not significant after controlling for empiric carbapenem, Pitt score 3 and K. pneumoniae (OR 2.43, P = 0.073). None of the VF was associated with 30-day mortality. No association was found between 30-day mortality and any ESBL and AmpC beta-lactamases or VF when piperacillin-tazobactam or carbapenems were given. No significant association between 30-day mortality and active empiric therapy was found.Shi Thong HengSwaine L. ChenJoshua G. X. WongDavid C. LyeTat Ming NgNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Shi Thong Heng Swaine L. Chen Joshua G. X. Wong David C. Lye Tat Ming Ng No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia |
description |
Abstract The objective of this study was to correlate resistance mutations of extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases and virulence factors (VF) with 30-day mortality in patients treated with either piperacillin-tazobactam or carbapenems. A post-hoc analysis on 123 patients with ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia treated empirically with piperacillin-tazobactam and carbapenems was performed. Beta-lactamase resistance mutations and VF were identified by whole genome sequencing (WGS). The primary endpoint was 30-day mortality. Multivariate analyses were performed using logistic regression. WGS showed diverse multilocus sequence types (MLST) in 43 K. pneumoniae strains, while ST131 predominated in E. coli strains (57/80). CTX-M was most commonly detected (76/80 [95%] of E. coli; 39/43 [91%] of K pneumoniae.), followed by OXA (53/80 [66%] of E. coli; 34/43 [79%] of K. pneumoniae). A significant correlation was found between the number of genes encoding third-generation cephalosporin-resistant beta-lactamases and 30-day mortality (p = 0.045). The positive association was not significant after controlling for empiric carbapenem, Pitt score 3 and K. pneumoniae (OR 2.43, P = 0.073). None of the VF was associated with 30-day mortality. No association was found between 30-day mortality and any ESBL and AmpC beta-lactamases or VF when piperacillin-tazobactam or carbapenems were given. No significant association between 30-day mortality and active empiric therapy was found. |
format |
article |
author |
Shi Thong Heng Swaine L. Chen Joshua G. X. Wong David C. Lye Tat Ming Ng |
author_facet |
Shi Thong Heng Swaine L. Chen Joshua G. X. Wong David C. Lye Tat Ming Ng |
author_sort |
Shi Thong Heng |
title |
No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia |
title_short |
No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia |
title_full |
No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia |
title_fullStr |
No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia |
title_full_unstemmed |
No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia |
title_sort |
no association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant escherichia coli and klebsiella pneumoniae bacteremia |
publisher |
Nature Portfolio |
publishDate |
2018 |
url |
https://doaj.org/article/ae5796eed3b7401d9a83da28e86e78fd |
work_keys_str_mv |
AT shithongheng noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia AT swainelchen noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia AT joshuagxwong noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia AT davidclye noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia AT tatmingng noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia |
_version_ |
1718395418921926656 |